Circulating insulin-like growth factor II and colorectal adenomas.

@article{Renehan2000CirculatingIG,
  title={Circulating insulin-like growth factor II and colorectal adenomas.},
  author={Andrew G. Renehan and John E. Painter and Domhnall J. O’Halloran and Wendy S. Atkin and Christopher S. Potten and Sarah T O'dwyer and Stephen M. Shalet},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2000},
  volume={85 9},
  pages={
          3402-8
        }
}
Circulating insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) may be risk factors for the development of colorectal cancer. On the other hand, IGF-II and IGFBP-2 are overexpressed in colorectal carcinomas. These contrasting backgrounds led us to investigate the relationship between serum IGF-I, IGF-II, IGFBP-2, and IGFBP-3 and the presence of colorectal adenomas, known precursors of colorectal carcinoma, in 345 volunteers attending a screening flexible sigmoidoscopy trial… 
View on PubMed
academic.oup.com
79 Citations
Highly Influential Citations
1
Background Citations
32
Methods Citations
2
Results Citations
2

79 Citations

Citation Type

Citation Type

Insulin-like growth factor II and colorectal cancer risk in women.
  • K. Hunt, P. Toniolo, +7 authors R. Kaaks
  • Medicine, Biology
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 2002
TLDR
The results confirm those of three recent case-control studies and suggest a possible increase in colorectal cancer risk among subjects with comparatively elevated serum IGF-II, which is not growth hormone dependent and which do not vary with alterations in energy balance.
Plasma Insulin-Like Growth Factor I Is Inversely Associated with Colorectal Adenoma Recurrence: A Novel Hypothesis
TLDR
It is suggested that, once an adenoma is removed, higher IGF-I levels reduce the odds of the formation of new lesions in the colorectum.
Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps.
TLDR
The hypothesis that insulin and IGF-I may contribute to the development and advancement of adenomatous polyps is supported, and levels of IGF/IGFBP-3, and insulin are associated with adenomas and even more so with advanced adenoma.
Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer.
TLDR
IGBP-2 is a potential diagnostic and prognostic biomarker of CRC and LOI of IGF-II is significantly associated with poor prognosis in patients with stage IV disease.
Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT.
TLDR
The findings for IGF-I agree with previous results from PSA screening trials, but contrast with positive associations in routinely detected disease, suggesting that reducing levels of circulating IGF- I might not prevent the initiation of prostate cancer but might, nonetheless, prevent its progression.
Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer
TLDR
It is concluded that the serum IGF-II and IGFBP-2 profiles may provide insights into underlying biological mechanisms, and that serum IGF BP-2 may have an adjunct role in cancer surveillance in patients with colorectal cancer.
Insulin Resistance, Apoptosis, and Colorectal Adenoma Risk
TLDR
The results provide novel evidence that elevated insulin and glucose are associated with increased adenoma risk and decreased apoptosis in normal rectal mucosa and suggest that insulin may act early in the adenomas-carcinoma sequence to promote the development of colorectal adenomatous polyps.
Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma
TLDR
A significant positive association between circulating IGF1 levels and risk of advanced colorectal adenoma was shown, suggesting that IGF1 is associated with the pivotal precursor to coloreCTal cancer.
Plasma insulin, glucose, IGF-I, IGF-II, and IGFBP-3 and risk of recurrent colorectal adenomas.
TLDR
The results do not support a role for insulin biomarkers and recurrent colorectal adenomas.
Circulating levels of IGF-1, IGFBP-3, and IGF-1/IGFBP-3 molar ratio and colorectal adenomas: A meta-analysis.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.
TLDR
Ass associations of plasma levels of IGF-I and IGFBP-3 with the risk of colorectal cancer are suggested to be consistent during the first and the second 7-year follow-up intervals and among younger and older men.
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3
TLDR
Ass associations of plasma levels of IGF-I and IGFBP-3 with the risk of colorectal cancer are suggested to be consistent during the first and the second 7-year follow-up intervals and among younger and older men.
Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.
TLDR
Elevated serum IGF-1 levels may be an important predictor of risk for prostate cancer, but results do not support an important role for serum IGFBP-3 as a predictor ofrisk for this disease.
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
TLDR
A strong positive association was observed between IGF-I levels and prostate cancer risk, independent of baseline prostate-specific antigen levels, which may have implications for risk reduction and treatment.
Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon
TLDR
These findings suggest that the IGF-II/Man-6-P receptor may also be involved in development of adenocarcinoma of the colon, and there is rapidly accumulating evidence implicating the IGF system in the development of malignancy of the large bowel.
IGF‐I and IGF‐II in relation to colorectal cancer
TLDR
There is evidence that high levels of circulating IGF‐I and ‐II might be associated with colorectal cancer, though none of these relations reached statistical significance.
Can "big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia?
TLDR
Increased bioavailability ofbig IGF II in this complex due to unrestricted capillary passage and enhanced insulin bioactivity of this big IGF II pool provide a continuous increased insulin-like potential available to insulin and type 1 IGF receptors of insulin-sensitive tissues and thus may lead to sustained hypoglycemia.
Insulin‐like growth factor (IGF)–binding protein‐3 (IGFBP‐3) proteolysis in patients with colorectal cancer: possible association with the metastatic potential of the tumor
TLDR
Inhibition of IGFBP‐3 proteolysis and invasive properties of cancer cells are related in colorectal cancer patients, and elevated amounts of pro‐IGF‐II nor presence of detectable IGFBP-3 protease inhibitors in the circulation could explain the observed suppression of IGF BP‐3 proteins in IGF‐NM patients.
Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions.
TLDR
Endocrine Functions of IGFBPs in Serum A. to prevent insulin-like effects B. to increase the half-lives of IGFs C. to exert IGF-independent effects D to control the tra...
...
1
2
3
4
5
...